Skip to main content

Market Overview

Lilly, MiNA Ink Broad RNA Deal Worth $1.25B

Lilly, MiNA Ink Broad RNA Deal Worth $1.25B
  • Eli Lilly and Company (NYSE: LLYhas struck a deal with MiNA Therapeutics to develop small activating RNA (saRNA) candidates against up to five targets across its key therapeutic focus areas.
  • Lilly is paying $25 million upfront and committing to milestones of up to $245 million per target to work with MiNA.
  • MiNA will also receive tiered royalties from the low-single to low-double digits on product sales resulting from the collaboration.
  • Lilly is already active in the broader RNA space, having entered into deals with Avidity BiosciencesDicerna Pharmaceuticals, and Evox Therapeutics.
  • “Small activating RNAs are a promising new technology, which will expand the breadth of Lilly’s RNA therapeutics platform and the targets we can pursue. We are excited about the potential of combining MiNA’s leading saRNA platform and our expertise in new modalities to accelerate the development of RNA-based medicines in areas of high unmet medical need,” Andrew Adams, VP for new therapeutic modalities at Lilly, said in a statement.
  • Price Action: LLY shares are down 0.40% at $193.99 on the last check Tuesday.

Related Articles (LLY + DRNA)

View Comments and Join the Discussion!

Posted-In: BriefsBiotech News Health Care Contracts General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at